Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?-Reference-Cited by-同舟云学术

Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?

Published:2020-04-15 Issue:11 Volume:21 Page:1287-1298
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Bergonzini Cecilia¹,Leonetti Alessandro¹²,Tiseo Marcello²³,Giovannetti Elisa¹⁴,Peters Godefridus J.¹⁵^ORCID

Affiliation:

1. Amsterdam UMC, VU University Medical Center, Laboratory Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands

2. Medical Oncology Unit, University Hospital of Parma, Parma, Italy

3. Department of Medicine and Surgery, University of Parma, Parma, Italy

4. Cancer Pharmacology Lab, AIRC-Start-Up Unit, Fondazione Pisana per la Scienza, Pisa, Italy

5. Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1746269

Reference63 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Cancer statistics, 2019

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. The epidermal growth factor receptor family: Biology driving targeted therapeutics

5. Epidermal growth factor receptor mutations in lung cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells;Biomedicine & Pharmacotherapy;2024-07

2. The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib;Translational Cancer Research;2023-08

3. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer;BMJ Open Respiratory Research;2023-06

4. Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer;Beilstein Journal of Nanotechnology;2023-02-22

5. Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data;Cancers;2023-01-19